deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 certainty unassessable-11%- certainty unassessable-15%
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 certainty unassessablestatistically conclusive-26%- certainty unassessablestatistically conclusive-23%

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 certainty unassessablestatistically conclusive-15% certainty unassessable-10%-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant